Novo Nordisk A/S (NONOF)
| Market Cap | 315.80B |
| Revenue (ttm) | 43.92B |
| Net Income (ttm) | 15.16B |
| Shares Out | n/a |
| EPS (ttm) | 3.40 |
| PE Ratio | 20.83 |
| Forward PE | 17.50 |
| Dividend | 1.66 (2.28%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 10,902 |
| Average Volume | 99,846 |
| Open | 70.00 |
| Previous Close | 71.25 |
| Day's Range | 70.00 - 73.98 |
| 52-Week Range | 55.28 - 149.55 |
| Beta | 0.21 |
| RSI | 57.38 |
| Earnings Date | May 7, 2025 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsNews
Novo Nordisk faces fierce competition in China’s diabetes drug market
Competition in the mainland Chinese market for diabetes and weight loss drugs is set to intensify as more than 60 late-stage drug candidates are undergoing clinical trials, according to a recent repor...
The boomerang era: A slew of former CEOs are suiting up once more to take top roles at their old companies
From Novo Nordisk to UnitedHealth, former chief executives are returning to guide their former organization in times of trouble.
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly
Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.
Novo Nordisk's weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly's Zepbound, and now the company is trying to get back on track
Novo Nordisk's weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly's Zepbound, and now the company is trying to get back on track.
Veru's Enobosarm Shows Muscle In Wegovy Combo Trial
Penny stock Veru Inc. (NASDAQ: VERU) on Wednesday released topline safety results from the Phase 2b QUALITY study of enobosarm 3mg, enobosarm 6mg, or placebo to enhance fat loss and prevent muscle lo...
Novo Nordisk's Buy Scenario Is Supported By Quantitative Evidence
Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?
Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels.
Final Trade: ASML, XYZ, XLC, NVO
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Weight-loss drugs like Ozempic and Wegovy continue to be in high demand—and expensive. Are prices likely to come down soon?
The supply of GLP-1 drugs has been increasing, but they're still expensive for most patients. Here are answers to some questions consumers have.
Investment Case For Eli Lilly Still Weak Despite Novo Nordisk's Struggle
Is Novo Nordisk Immune To President Trump's Drug Price Plans
Novo Nordisk’s hunt for boss with Danish values — and US commercial nous
Jørgensen’s ousting unusual for group where CEOs have had smooth transitions after long tenures
Should everyone be taking drugs like Ozempic? Drugs in the GLP-1-category show promise for a growing list of health conditions
GLP-1 drugs for weight loss and treating diabetes show promise for an ever-expanding list of diseases.
Final Trade: AAPL, NVO, TLT, X
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Mizuho's Jared Holz talks what is next for Novo Nordisk
Mizuho's Jared Holz joins 'Fast Money' to talk what is next for Novo Nordisk as the stock struggles.
Mizuho's Jared Holz talks what is next for Novo Nordisk
Mizuho's Jared Holz joins 'Fast Money' to talk what is next for Novo Nordisk as the stock struggles.
Novo Nordisk's High Risk/Reward Proposition: 129% Rally Or 65% Drop?
Novo Nordisk A/S ( NOVO-B) has entered the 18th and final phase of its long-term Weekly Adhishthana Cycle, marking a potentially transformative period. While the weekly charts point to a possible Nirv...
Novo Nordisk's High Risk/Reward Proposition: 129% Rally Or 65% Drop?
Novo Nordisk A/S (NOVO-B) has entered the 18th and final phase of its long-term Weekly Adhishthana Cycle, marking a potentially transformative period. While the weekly charts point to a possible Nirva...
Novo Nordisk promotes Wegovy for new customers as compounding ban takes effect
Novo Nordisk offers Wegovy for $199 for first month to new cash-paying customers
Novo Nordisk said on Thursday it is offering self-paying patients who are new to its weight loss drug Wegovy their first month of medicine for $199 through June 30.
New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect
With all doses of FDA-approved Wegovy® fully available nationwide, it is illegal under US compounding laws to make or sell knockoff "semaglutide" drugs, with rare exceptions New, one-time $199 first-m...
Focus: Novo Nordisk's former chief makes comeback to steer choice of new CEO
Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press conference in Copenhagen: "You ain't seen nothing yet."
Pressure is mounting on Lund at BP and Novo Nordisk
The Norwegian has become a lightning rod for shareholder criticism as chair of both companies
Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
Cigna's pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.
Novo Nordisk Foundation pledges $57 million to WHO amid US funding gap
The Novo Nordisk Foundation has pledged up to DKK 380 million ($57.76 million) to the World Health Organization (WHO) to expand its tie-up with the United Nations agency for another four years, the ph...